ALBUQUERQUE, N.M., May 17 /PRNewswire-FirstCall/ -- Biomoda, Inc. , Albuquerque, New Mexico, (http://www.biomoda.com), maker of patented early lung cancer detection testing and other cancer diagnostic technology, said today that it is expanding its patent portfolio with an additional patent pending for the use of its patented porphyrin molecule as part of a sophisticated cancer drug delivery system.
“The porphyrin molecule, which resembles a key component of blood, could be used in vivo to deliver a drug directly into a cancer tumor as part of cancer therapy because of its affinity and ability to carry or piggyback other molecules and various metals,” said John Cousins, President of Biomoda. “It also could play a significant role in imaging human cancer.”
“We are building a patent portfolio to protect the many uses of this extraordinary molecule,” Mr. Cousins said. “For instance, the patented porphyrin molecule binds to cancerous or pre-cancerous cells extracted from body fluids and the cancerous cells subsequently glow red under a florescent light, allowing detection under a microscope. Normal cells will not fluoresce,” Mr. Cousins said.
“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Biomoda, Inc., Albuquerque John Cousins, President 505-821-0875 Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Biomoda, Inc.
CONTACT: John Cousins, President of Biomoda, Inc., +1-505-821-0875; orPaul Knopick of E & E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for Biomoda, Inc.
